Tatva Chintan Pharma Chem Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Tatva Chintan Pharma Chem Limited's yearly results (2023–2026), compared with Basic Materials companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹46 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹43 tied up three years earlier. More money tied up than 87% of Basic Materials companies in India.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Basic Materials companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹198Over the last 3 years, every ₹100 of reported profit came with ₹198 of operating cash.
Higher than 84% of Basic Materials companies in India.
Self-Funding Ratio
0.5×Over the last 3 years its own operating cash paid for 48% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 75% of Basic Materials companies in India.
Cash Locked Ratio
₹46For every ₹100 of sales, ₹46 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹43 tied up three years earlier.
More money tied up than 87% of Basic Materials companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Basic Materials companies in India.
Growth Efficiency Ratio
−₹4Sales grew 19% in 3 years, but profit fell: ₹4 less profit per ₹100 of extra sales.
Lower than 79% of Basic Materials companies in India.
Asset Productivity Ratio
+19% / +32%In 3 years sales changed by +19% while total assets changed by +32%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.3×Debt due within a year is covered 0.3 times by its yearly operating cash.
Lower than 68% of Basic Materials companies in India.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Higher than 60% of Basic Materials companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 65% of Basic Materials companies in India.
Tangible Net Worth Ratio
99%Of every ₹100 of net worth, ₹99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 61% of Basic Materials companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Tatva Chintan Pharma Chem Limited owes ₹0.22 for every ₹1 it owns. Net profit rose 636% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Compared with Basic Materials companies in India · latest annual results Mar 2026.
P/E ratio
75.7Investors pay ₹75.7 for every ₹1 of Tatva Chintan Pharma Chem Limited's yearly profit, higher than 91% of Basic Materials companies in India.
P/B ratio
4.98The share price is 4.98 times Tatva Chintan Pharma Chem Limited's book value per share, higher than 85% of Basic Materials companies in India.
Market cap
₹3,893 CrThe total market value of all of Tatva Chintan Pharma Chem Limited's shares at today's price (share price × number of shares), larger than 65% of Basic Materials companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹782 CrWhat Tatva Chintan Pharma Chem Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹334.20Net worth divided by the number of shares. The share price of ₹1,664 is 5.0 times this, which is the P/B above.
Return on equity (ROE)
6.6%Tatva Chintan Pharma Chem Limited earned 6.6% on its shareholders' money over the last year, lower than 66% of Basic Materials companies in India.
Owes vs Owns
0.22×Tatva Chintan Pharma Chem Limited owes ₹0.22 for every ₹1 it owns (low), lower than 76% of Basic Materials companies in India.
Dividend yield
0.11%Tatva Chintan Pharma Chem Limited pays 0.11% of its share price as dividends a year, lower than 91% of dividend-paying Basic Materials companies in India.
Revenue growth
+32%Revenue rose 32% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Profit growth
+636%Net profit rose 636% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Profit margin
8.4%Tatva Chintan Pharma Chem Limited keeps ₹8 of every ₹100 of revenue as net profit.
Cash quality
0.7×Cash from Tatva Chintan Pharma Chem Limited's business was 0.7× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
22.7×Tatva Chintan Pharma Chem Limited's operating profit covered its interest costs 22.7 times in the year to Mar 2026.
Cash vs debt
Net debtTatva Chintan Pharma Chem Limited had ₹114 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Tatva Chintan Pharma Chem Limited's P/E ratio?
Investors pay ₹75.7 for every ₹1 of Tatva Chintan Pharma Chem Limited's yearly profit, higher than 91% of Basic Materials companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Tatva Chintan Pharma Chem Limited: ₹3,893 Cr ÷ ₹782 Cr (31 Mar 2026) = 5.0.
What is Tatva Chintan Pharma Chem Limited's return on equity?
Tatva Chintan Pharma Chem Limited earned 6.6% on its shareholders' money over the last year, lower than 66% of Basic Materials companies in India.
How much does Tatva Chintan Pharma Chem Limited owe compared with what it owns?
Tatva Chintan Pharma Chem Limited owes ₹0.22 for every ₹1 it owns (low), lower than 76% of Basic Materials companies in India.
Does Tatva Chintan Pharma Chem Limited pay a dividend?
Yes. Tatva Chintan Pharma Chem Limited pays 0.11% of its share price as dividends a year, lower than 91% of dividend-paying Basic Materials companies in India.
Is Tatva Chintan Pharma Chem Limited's revenue growing?
Revenue rose 32% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.